cedhys business tour in israËl 5th to 11th november 2012 1cedhys business tour in israël

CEDHYS Business tour in ISRAËL

5th to 11th November 2012

1CEDHYS Business tour in Israël

Table of contents

Attendees presentation


BIOGARAN: Antoine JUMELLE June 2010 – Present (2 years 3 months): CIO of BIOGARAN Biogaran is the second

Pharmaceutical Generic's Laboratory in France.

2001 – June 2010 (9 years) IT Division Manager at Servier Privately Held; 10,001+ employees; Pharmaceuticals industry+ IT Quality Manager+ IT Security Survey Manager+ International IT Coordination (140 countries)+ Project Leader SAP Finance for the main French affiliate

1996 – 2001 (5 years): IT Department Manager at Servier

Technical & Support Department (2500 users)- Workstations Policy (Harware-Software-Contract Negociations)- Supports (2500 users - 25 000 calls / year)- Networks LAN/CAN- Movings

CEDHYS Business tour in Israël 3

French Laboratory, Biogaran markets more than 530 generic medications. His philosophy is to produce all genericable molecules, the blockbuster drug and more confidential. Whatever the origin of the laboratory "princeps" (parent drug).Results: a range that can treat more than 80 diseases.Biogaran goes further: the laboratory since its inception has become an ethical approach that recognizes the limits of medicine. For Biogaran drugs are active substances to be used properly. His commitment is backed by concrete actions towards a better use of medicines and better monitoring of treatment (compliance) by the patient. Biogaran invests a portion of its profits in this process through the establishment of free services (or cost): Tools secure daily use of the drug (creation of packages which facilitate the transmission of treatment doctor, pharmacist and patient, clear and legible notices)Services to reduce certain risk behaviors among young women (creating a mobile cover to reduce opportunities to forget his regular contraception)Services to reduce certain risk behaviors among children (creation of the case Médikid to promote safer treatments transmission between nearby)Services to facilitate the practice of medication at home.

BOUCHARA-RECORDATI: Jean VINCENEUX Since 2005: BOUCHARA RECORDATI (400 employees)

IT MANAGER – FRANCE Laboratoires BOUCHARA RECORDATI is a subsidiary of RECORDATI group, located in Milan.I have the responsibility of IT department for all sites in France, including theadministrative offices (Levallois-Perret), the factories (St-Victor and Nanterre) andORPHAN Europe Company (Paris – La Défense). I report directly to RECORDATI CIO

From 2004 to 2005: BOUCHARA RECORDATI (400 employees)IT Project managerI was responsible for implementation of different IT projects especially for SAPsoftware, sales and distribution modules


Recordati, established in 1926, is a European pharmaceutical group, listed on theItalian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 3,200, dedicated to the research, development,manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy,operations in the main European countries, in Central and Eastern Europe and inTurkey. A field force of around 1,700 medical representatives promotes a wide rangeof innovative pharmaceuticals, both proprietary and under license, in a number oftherapeutic areas including a specialized business dedicated to treatments for rarediseases. Recordati is a partner of choice for new product licenses from companieswhich do not have a European presence. Recordati is committed to the researchand development of new drug entities within the cardiovascular and urogenitaltherapeutic areas and of treatments for rare diseases. Consolidated revenue for 2011was € 762.0 million, operating income was € 163.5 million and net income was €116.4 million.

CEVA: François TRICOT Chief Information Officer at CEVA Santé Animale Over 15 years of multicultural experience in the IT industry, in various management

positions (Skill Centre Manager, Cief Information Officer) April 2008 - Present (4 years 5 months):

- Transform group IT to match the challenges of today and tomorrow- Foster organisation and structure

February 2006 - March 2008 (2 years 2 months): Manager at Aspire Aspire is the largest Capgemini outsourcing services project with more than 5000 staff

delivering IT solutions to HMRC, the UK tax agency- Implemented productivity improvements in the Test discipline (a 400 people skill centre),- Industrialised delivery practices for productivity improvements - Accelerated Delivery Centre (a

200 peoplebusiness unit),- Defined architecture principles of a massively scalable architecture for the HMRC internet portal

(severalmillion users, peak usage for Self-Assessment) (a 100 people project)


Ceva Santé Animale is one of the Top 10 veterinary health company. Ceva's expertise centres are on the twofields of pharmacology and biology, and has dedicated teams that aim to meet the specific demands of thecompanion animal, poultry, ruminant and swine sectors. Ceva's operation are all around the globe in 42 countries,with 21 factories and 13 R&D centers. About 3000 people work at Ceva and the fast growing turnover is above500 M€.

DANONE Research: Laurent ANTIBI Information Systems Director Danone Group

February 2007 – Present (5 years 8 months)Information Systems Director in charge of R&D function and Research Centers

June 2003 – January 2007 (3 years 8 months) Danone Group Head QuartersProject Director in charge of CRM and Web Solutions

September 2000 – May 2003 (2 years 9 months) Danone headquartersCRM IS Manager : Multichanel Marketing Campain Management - consumer database


Danone Group, a french company , world leader in food industry101 000 people / 19,3 b€ turn over4 divisions : Dairy, Waters, Baby Food, Medical NutritionNutrition for Health is at the heart of Danone ‘s Strategy

Flamel Technologies: Raphaël COMMARET

Information Technology Manager, since 2003Flamel Technologies R&D, Pharmaceutical Industry (~250 employees)Also in charge of the compliance of IT systems with FDA regulation and Sarbanes-Oxley act.

2000-2003: Accenture Consulting & technology services company: IT consultant


Flamel Technologies SA (NASDAQ: FLML) is a leading drug delivery company focused on the goalof developing safer, more efficacious formulations of drugs to tackle unmet medical needs.

Our product development pipeline includes biological and chemical drugs formulated with ourproprietary platforms :

- Medusa platform (injectable drugs) allows formulation and/or extended release of biologics(including proteins, antibodies and peptides) and also small molecules.Several Medusa-based products are at various clinical stages of development; Medusa’s leadinternal product candidate IFN-a XL is currently the subject of a Phase 2 trial in HCV patients.DeliVax®, Medusa’s vaccine application, permits the efficient formulation of vaccines.

- Micropump platform (oral drugs) allows formulation and controlled release of chemical drugsthat are best absorbed in the small intestine.

- LiquiTime® allows extended release liquid formulations of drugs for patients who have difficultyswallowing tablets or capsules, particularly children and the elderly.

- Trigger Lock™ allows tamper-resistant controlled release formulations of narcotics and otherdrugs susceptible to abuse.

GALDERMA: Thierry BARSALOUDr. Thierry Barsalou is Chief Information Officer for Galderma, a fully integrated

pharmaceutical

company exclusively focused on dermatology. As CIO, Thierry has global responsibility over

Information Technology throughout the company. Thierry brings 30 years of experience in

the technology and healthcare industries alternating between successful start-ups and varied

positions of increasing responsibility at large companies such as IBM, Novartis and Ipsen. He

has lived and worked in France, the US, Switzerland, Canada and Belgium. Thierry holds an

MD degree from University of Paris, France, and a PhD in Medical Information Sciences from

Stanford University.


Galderma is a global pharmaceutical company founded in 1981 and exclusively focused ondermatology. The company has 31 wholly-owned affiliates and 4,000 employees. Galderma’sextensive product portfolio treats a range of dermatological conditions including: acne, rosacea,onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancerand medical solutions for skin senescence. In 2011, Galderma acquired Q-Med, a Swedishmedical device company specialized in aesthetics, strengthening Galderma’s presence in theaesthetic and corrective market. With approximately 19% of revenues invested each year todiscover and develop new products and access innovative technologies, the company is one ofthe world’s leading investors in dermatology R&D.

LFB: Jean-Louis QUEVA 2004 – Present (8 years): CIO at LFB

2001 – 2003 (3 years): Hypermarket CIO at CARREFOUR

1996 – 2001 (5 years): International Project Manager at AIR LIQUIDE


LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in major therapeutic areas: immunology, haemostasis, and intensive care. LFB group is the leading manufacturer of plasma-derived medicinal products in France and the 6th largest player worldwide. It is also among the leading European companies in the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong research activities, LFB group is developing a growth strategy to expand its business activities by offering new therapeutic treatments and expanding into new international markets.

NUTRICIA: France GENNEQUIN Since Feb.2009 : IS Director of NUTRICIA

2001 – 2008 : DANONE GROUP :

o 2004 – 2008 : IT Operations Project Manager + Application Administration Manager

In charge of the projects for all IT Operations of Danone – 33 customer companies, 8000 users, worldwide implementation. Coordination of 120 IT People.

o 2003 : IS Deployment Manager : Dannon US & Danone Canada

In charge of the deployment of SAP in Danone Canada and The Dannon Company, Inc.

o 2001 – 2002 : Development Manager of Danone Group

In charge of realizing all R/3 developments for the Core SAP System of Danone and for the 1s deployment wave

2000 : Deployment Project Manager at SODEXHO acting as Director of the SAP Competency Center

1999 : SAP Consultant at CMG

1997 : Study & Development Engineer at AXA


Nutricia Nutrition Clinique SAS is the French business unit of « Medical Nutrition »division of Danone Group. Our products are intended for the nutritional managementof diseases and medical conditions (malnourished adults, metabolic disorder,complete nutrition for patients who cannot meet their nutritional needs orally, etc.).They are used under the direction of Healthcare professionals.

Nutricia Nutrition Clinique sells & distributes nutrition products via several distributioncanals (Pharmacies, Hospitals, Wholesalers, Homecare professionals) in France andexport (DOM-POM, Maghreb). It is a business unit of 180 employees (half salesforce, half HQ) for a 2011 CA of 107 M€

STAGO: Jean-Marc OBENICHE Since 2010 : STAGO, DIRECTOR IT – in charge of innovations and management control.

1993 – 2010 : STAGO, C.I.O.

1989 – 1993 : FROMAGERIES BEL – Cheese maker company (Laughing cow, Babybel..), Development Manager

1985 – 1989 : Laboratoires JANSSEN- (JOHNSON & JOHNSON affiliate) Office automation and Lan Manager


Stago is a pharmaceutical laboratory, founded in 1945, which now operates in theIn vitro Diagnosis (IVD) industry, wholly dedicated to the exploration of haemostasisand thrombosis. (Reagents and devices)

STALLERGENES: Thierry GREHAIGNE from 1996 till today STALLERGENES S.A., Pharmaceutical lab, Worldwide leader in

immunotherapy (desensitization to allergies). 250M€ of revenues, 40% out of France. 1.000 employees.

Vice-President Information Technologies Staff : 35 people, annual OPEX : 3,5 M€, annual CAPEX : 4,5 M€ Building of a new Corporate Information System (based on M3, ERP from

LAWSON/INFOR Company) with deployment throughout Headquarters and affiliates

Implementation of E.DI. flows with third-party companies, for payment of the delivered products to patients (more than 3.000 deliveries per day)

Due diligence coordination before acquisition of a competitor Implementation of a new Company organization for management of

transformation and product development projects.

From1994 to 1996 CORNING FRANCE, Scientific & ophthalmic glass manufacturer, affiliate of CORNING Inc., worldwide leader in technical glass and optical fiber. 450 MF of turnover, 70% out of France. 600 employees.

Supply chain & IT Director


Stallergenes is a European biopharmaceutical company dedicated to the treatment of allergy-related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma, using allergen immunotherapy. The leader in sublingual immunotherapy treatment, Stallergenes devotes almost 20% of its gross sales to Research & Development and is actively involved in the development of a new therapeutic class: sublingual immunotherapy tablets. In 2011, the company had sales of € 235 million, and more than 500,000 patients were treated with Stallergenes products.

URGO: Patrice CAULFUTY January 2003 – Present (8 years 9 months): Chief Information Officer (CIO) of

Laboratoires Urgo Privately Held; 1300 employees; Pharmaceuticals industry (manufacture solutions to treat common ailments and high-tech healing products)Define the IT strategy and policy (ERP SAP, Development, Lan, Wan, Labtop, web …)Management of the IT Department (20 people)International IT Coordination (15 affiliates)IT Quality Manager (FDA compliance)Responsible for SAP Roll out projects in Europe and Asia (5 countries)Roll out CRM SalesForce and CLM (Skura) software in Asia

1998 – 2002 (4 years): IT Department Manager at Laboratoires Fournier Privately Held; 4000+ employees; Pharmaceuticals industrySAP skill Department manager (10 people)Support and maintenance in SAP (upgrade, customizing …) IT Security ManagerRoll out SAP in 5 countries


Laboratoires Urgo’s Healthcare Division focuses its expertise on reference brands: Urgo, the top foot, hand and wound care brand is extending its leadership to mouth wounds with Urgo Mouth Ulcers and Cold Sores. Humex, No. 1 in the upper respiratory tract infection market, is strongly positioned in the cold and allergysegments with, in particular, its hay fever treatment containing Beclomethasone. A historic player in these markets, Urgo Healthcare expanded its expertise to create a third major section dedicated tovitamin supplements in 2004. The launch of ImmunoStim in 2006 and the acquisition of Alvityl in 2008 have enabled it to further strengthen its position and become a key player in the child and family health segment.Urgo Healthcare makes the health URGO & HUMEXof these “consum-actors” its central focus, offeringthem safe, effective and innovative products.Voted most innovative OTC company in pharmacies in 2009, Urgo Healthcare is continuing to grow thanks to its drive for innovation and expertise, enabling it to offer its customers advanced, high-tech solutions.

*

URGO MEDICAL,a reference for health professionalsUrgo Medical, a wound-healing expert, is committed to workingwith health professionals day after day to advance knowledge inthe field of wounds and develop innovative treatments designedto improve patients’ quality of life and help them heal more quickly.Today, Urgo Medical offers high-tech solutions for the treatmentof serious and incapacitating conditions: burns, pressure sores, legulcers, epidermolysis bullosa, diabetic foot ulcers. Urgo Medical’steams strive on a daily basis to meet their commitment to relieve pain,simplify treatments and make life easier for patients.In 2000, Urgo Medical revolutionised the wound healingmarket by inventing Technology Lipido-Colloid (TLC) – leading to thedevelopment of Urgotul® – establishing itself as the gold standardin the management of acute wounds.Using “Pressure System” technology developed as a result ofUrgo Research, Urgo Medical created the first compression system with two active bandages in 2008: UrgoK2. In 2011, a new technological and scientific advance with UrgoStart*, a healing accelerator treatment.

VETOQUINOL: Pierre-Yves COLIN 12/06- now : VETOQUINOL (Lure) – Group Director, Information System Member of

Group Steering CommitteeDefinition and implementation of IT strategy of Vetoquinol Group. Management of IT team (40 people). Annual budget 6,5 M€ over 24 affiliates.Creation and structuration of Group IT Department, JDEdwards ERP Programm roll out in Spain, Poland, India, USA. Implementation of LIMS, Group CRM, Business Intelligence.Direct management of IT of several affiliates : USA, Canada and India.

01/03- 12/06 : GROSFILLEX (Oyonnax) – Organization and Information System DirectorDefinition and implementation of the IT Strategy of Grosfillex. Management of IT teams (20people). Direct management of USA and Russia’s IT.Business process redesign projects : French logistic reorganization (charter, transport planification and purchases), audit of material flows (semi-finished) within “Window” division then implementation of tracability, monitoring procedures and dashboards. Implementation of new logistic standards regarding transportation costs.North America : Audit and improvement (sales forecasts, production planification, supply).Implementation of MOVEX ERP. Russia : Active participation to the creation of the russian affiliate (back-office, industrial andlogistics) Implementation of 1C local ERP.


The 10th largest veterinary pharmaceutical company in the world and the 3rd largest dedicated to animal health, Vétoquinol is first and foremost an independent, family-owned business. Deeply committed to its values, it has always enjoyed a close relationship with its vet clients. Vétoquinol’s growth and development strategy focuses on innovation and finding the right balance between two major markets: companion animals and livestock, bred for human food. Historically based in France, Vétoquinol currently develops, produces and distributes a wide range of more than 700 medical and non-medical products in Europe, Americas and Asia-Pacific. With a presence in 23 countries through its subsidiaries, its strong network of 140 distributor partners provides visibility for its products in more than 100 countries.

VIRBAC: Patrick LALOUETTE Since 02/2002 : CIO of VIRBAC SA (French Group) with 3500 p (35 subsidiaries / 8 plants

worldwide) PHARMACY – Animal Health

2001-2002: CIO of LVMH Fashion Group Division 4Mds Eu (13 brands & 220p in IT .) LUXURY AND LEATHER GOODS (Vuitton, Kenzo, Celine, Givenchy, Lacroix, etc. ..) (Distribution - Retail with 980 stores)

1998-2001 CIO division of VIVENDI UNIVERSAL PUBLISHING 1100 p 1 billion (+100p. in IT) SERVICES


Founded in 1968 in Carros, near Nice, Virbac is dedicated exclusively to animal health. With a turnover of 623 million euros in 2011, the company now occupies 8th veterinarian pharmaceutical group worldwide.

Its wide range of vaccines and medicines used to prevent and treat major diseases of pets and livestock.

cedhys business tour in israËl 5th to 11th november 2012 1cedhys business tour in israël

Documents